Lentiviral Vectors Market, By Product Type (1st-generation, 2nd-generation, and 3rd-generation), By Indication (HIV, ß-thalassemia, X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy, and Wiskott-Aldrich Syndrome), By End User (Hospitals, Clinics

Lentiviral Vectors Market, By Product Type (1st-generation, 2nd-generation, and 3rd-generation), By Indication (HIV, β-thalassemia, X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy, and Wiskott-Aldrich Syndrome), By End User (Hospitals, Clinics, and Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Lentiviral vectors are potential gene transfer vehicles used in both research and gene therapy applications. Lentiviral vectors have the capacity to stably express a gene of interest in non-dividing and diving cells, which makes them efficient vehicles for gene transfer. Lentiviral vectors are used for the treatment of various rare genetic disorders such as β-thalassemia, X-linked Adrenoleukodystrophy, X-linked severe combined immunodeficiency (SCID-X1) and Metachromatic Leukodystrophy. Moreover, various market players are focusing on increasing their research and development activities for gene therapies including lentiviral vectors, in order to enhance their product portfolio, which is expected to drive growth of the global lentiviral vectors market over the forecast period. For instance, in May, 2021, Avrobio Inc. initiated a phase I/II trial for lentiviral vector gene therapy including AVR-RD-02 for patients with type 1 Gaucher disease.
Market Dynamics
Market players are focusing on adopting various inorganic growth strategies such as agreements, acquisitions, partnerships, and collaborations, in order to strengthen their market presence, which is expected to drive growth of the global lentiviral vectors market over the forecast period. For instance, on April 07, 2022, SIRION Biotech GmbH announced that it entered into an agreement with Beam Therapeutics, a biotechnology company, which is focusing on the use of CRISPR technology for the development of advanced genetic medicines. Under this agreement, SIRION Biotech GmbH provided the non-exclusive access of its proprietary lentiviral transduction enhancer LentiBOOST, to Beam Therapeutics for clinical development and commercialization of CAR-T programs.
Key features of the study:
This report provides in-depth analysis of the global lentiviral vectors market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global lentiviral vectors market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Thermo Fisher Scientific, Sirion-Biotech GmbH, Vigene Biosciences, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, and bluebird bio, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global lentiviral vectors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lentiviral vectors market

Detailed Segmentation:
Global Lentiviral Vectors Market, By Product Type:
1st-generation
2nd-generation
3rd-generation
Global Lentiviral Vectors Market, By Indication:
HIV
β-thalassemia
X-linked Adrenoleukodystrophy
Metachromatic Leukodystrophy
Wiskott-Aldrich Syndrome
Global Lentiviral Vectors Market, By End User:
Hospitals
Clinics
Research Institutes
Global Lentiviral Vectors Market, By Region:
North America
By Product Type:
1st-generation
2nd-generation
3rd-generation
By Indication
HIV
β-thalassemia
X-linked Adrenoleukodystrophy
Metachromatic Leukodystrophy
Wiskott-Aldrich Syndrome
By End User:
Hospitals
Clinics
Research Institutes
By Country:
U.S.
Canada
Latin America
By Product Type:
1st-generation
2nd-generation
3rd-generation
By Indication
HIV
β-thalassemia
X-linked Adrenoleukodystrophy
Metachromatic Leukodystrophy
Wiskott-Aldrich Syndrome
By End User:
Hospitals
Clinics
Research Institutes
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
1st-generation
2nd-generation
3rd-generation
By Indication
HIV
β-thalassemia
X-linked Adrenoleukodystrophy
Metachromatic Leukodystrophy
Wiskott-Aldrich Syndrome
By End User:
Hospitals
Clinics
Research Institutes
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type:
1st-generation
2nd-generation
3rd-generation
By Indication
HIV
β-thalassemia
X-linked Adrenoleukodystrophy
Metachromatic Leukodystrophy
Wiskott-Aldrich Syndrome
By End User:
Hospitals
Clinics
Research Institutes
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
1st-generation
2nd-generation
3rd-generation
By Indication
HIV
β-thalassemia
X-linked Adrenoleukodystrophy
Metachromatic Leukodystrophy
Wiskott-Aldrich Syndrome
By End User:
Hospitals
Clinics
Research Institutes
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
1st-generation
2nd-generation
3rd-generation
By Indication
HIV
β-thalassemia
X-linked Adrenoleukodystrophy
Metachromatic Leukodystrophy
Wiskott-Aldrich Syndrome
By End User:
Hospitals
Clinics
Research Institutes
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Thermo Fisher Scientific*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Sirion-Biotech GmbH
Vigene Biosciences
OriGene Technologies, Inc.
SignaGen Laboratories
Sino Biological Inc.
Takara Bio Inc.
Cell Biolabs, Inc.
GenTarget Inc.
GENEMEDI
bluebird bio, Inc.
“*” marked represents similar segmentation in other categories in the respective section.